Format

Send to

Choose Destination
Pediatr Infect Dis J. 1997 Aug;16(8):763-7.

Prospective study of fluconazole therapy in systemic neonatal fungal infection.

Author information

1
Department of Paediatrics, Baragwanath Hospital, University of the Witwatersrand, South Africa.

Abstract

BACKGROUND:

Standard neonatal systemic antifungal therapy with amphotericin B and flucytosine can be associated with toxicity, drug resistance and the need for prolonged venous access. There is consequently a need for alternative treatment options.

OBJECTIVES:

To assess the efficacy and safety of fluconazole in the treatment of systemic neonatal fungal infections.

METHOD:

Open, nonrandomized evaluation of fluconazole treatment in 20 consecutively enrolled neonates with systemic fungal infection.

RESULTS:

Clinical and microbiologic cure was achieved in 12 of 19 (63%) of infants treated. One additional infant received prior amphotericin B therapy and is included for assessment of side effects. One infant with Torulopsis glabrata infection failed treatment. Six infants died of Gram-negative bacterial infection and other intercurrent medical problems.

CONCLUSION:

Fluconazole appeared to be safe and effective for treatment of systemic candidal infection in the neonate although more data are required in very low birth weight infants.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center